In an article in Pharmexec, May 2024, the author identified seven essential attributes that investors look for before investing in Life Sciences. Among the seven was a “proven management team”. And this was described as “paramount”.
I remembered seeing something similar in Excedr’s online piece on ‘Top VC Firms for Biotech in 2024: Supporting Innovation & Growth’, where they cited “fostering a strong management team” as “the biggest factor that smart investors consider”.
“But what does this actually mean?” and “What capabilities are investors wanting to see?”, I remember…
by Alicia Gailliez, Business Development Manager, One Nucleus
This year’s ON Helix conference at the Babraham Research Campus brought together biotech innovators, service providers, pharma leaders, investors, and academics in an interactive atmosphere to explore cutting-edge developments in tools, therapeutics, devices, and ecosystems that are shaping the future of translational research.
More than just a translational research conference, ON Helix creates a space to address the most pressing scientific challenges facing our community and crucially to explore solutions that accelerate the…
There are times when it can feel like a small world when chance meetings and connections are encountered. On the flip side, when a company is seeking the right investor, collaborator or client, then the world can seem awfully big without some guidance of where to look.
Biotech and Pharma Investment Raised Between June 2020 and June 2025
With the global deal count and investment raised remaining somewhat challenged, then perhaps the dealmaker’s world feels smaller but less connected. The UK, accounting for around approximately 7% of total investment raised and deal…
By Monalisa Breazu, Learning & Development Administrator
In today's competitive and challenging life sciences landscape, your people truly are your most valuable asset when convincing investors, partners, and customers to believe you can execute plans effectively. Competition for the most talented, skilled professionals in all roles is always intense, with the options open to companies being (i) buy it in ready-trained; (ii) borrow it via outsourcing; or (iii) grow your own. Growing your own can take time and budget when resources are stretched like now, but it can be the most effective…
by Tony Jones, CEO, One Nucleus
Photography by www.SimonCallaghanPhotography.com
Posing the question to myself of whether networking has impacted my career and professional life, then I feel the short answer is an absolute yes. Given I am CEO at an organisation that, among other forms of support, delivers networking opportunities for employees of our member organisations, that may not be too surprising, you may think. Let me explain why I think networking has been key to my career journey, and perhaps it will then also explain why I’ve ended up in the role I am in – a logic I had not…
By Philippa Clark, Director of Business Development, One Nucleus
There’s a familiar refrain when One Nucleus speaks to early-stage life science start-ups: “We’re not quite ready to join yet.” With no lab space, no formal team, and still pre-funding, it’s totally understandable. Founders are head down, focused on survival, science, and reaching their next milestone. But that’s exactly why now is the right time to plug into a network like One Nucleus. Waiting until things are more established may mean missing out on the very support, visibility, and connections that help start-ups get to that…
In 2023, we surveyed hundreds of research scientists, lab operations, and procurement professionals across various biotech and pharmaceutical R&D labs. The results painted a vivid picture of today’s lab supply procurement process’s inefficiency and the complexities of P2P/S2P implementation due to the uniqueness of the R&D space.
Join us for an insightful webinar as we delve into survey results and explore innovative marketplace solutions that address these issues head-on. During this webinar, you will learn how to:
1. Save time searching for products and suppliers2. Track all your…
As part of our commitment to enabling member success and sharing best practices from peers, One Nucleus hosted a roundtable bringing together procurement and legal experts. What emerged from these discussions was a clear understanding that procurement can significantly impact your investor story, making it an extremely valuable lever for growth.
The roundtable focused on developing a strategic approach to procurement processes within life science organisations of all types and sizes. The presenters, Mark Hollison of Biotech Procurement Solutions and Rachel Bradley of Penningtons Manches…
by Tony Jones, CEO, One Nucleus
As everyone heads into the summer break with the sun shining and batteries in need of recharging, it is only natural that for many, thoughts turn to what is coming up after the vacation and what is on the wish list to achieve by the end of 2025.
As the first half of the year has demonstrated, from the optimism many entered JPM Week 2025 with at the start of January, described at Genesis 2024. to the challenging impact of the impending world events and political change, the unexpected can happen in the world of biotech. Whilst the funding and deal landscape…
By Monalisa Breazu, Learning & Development Administrator
In the life sciences sector, we talk a lot about innovation, regulation, and breakthroughs, but how often do we stop to think about how well the entire organisation understands the journey from lab bench to market launch?
For those in scientific roles, the stages of drug development are often familiar territory, That said, knowledge gaps can still exist between the Research and Development stages even within the same organisation. In an era of increasingly multi-disciplinary approaches to R&D. team cohesion can be an even…